These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26766493)
61. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells. Li C; Guan X; Xue H; Wang P; Wang M; Gai X Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760 [TBL] [Abstract][Full Text] [Related]
62. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Orlowski S; Mir LM; Belehradek J; Garrigos M Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):515-22. PubMed ID: 8713080 [TBL] [Abstract][Full Text] [Related]
63. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Tran VH; Marks D; Duke RK; Bebawy M; Duke CC; Roufogalis BD Nutr Cancer; 2011; 63(3):435-43. PubMed ID: 21462089 [TBL] [Abstract][Full Text] [Related]
64. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Fong WF; Shen XL; Globisch C; Wiese M; Chen GY; Zhu GY; Yu ZL; Tse AK; Hu YJ Bioorg Med Chem; 2008 Apr; 16(7):3694-703. PubMed ID: 18313307 [TBL] [Abstract][Full Text] [Related]
65. Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells. Kamioka H; Edaki K; Kasahara H; Tomono T; Yano K; Ogihara T J Pharm Pharmacol; 2021 Dec; 73(12):1609-1616. PubMed ID: 34313784 [TBL] [Abstract][Full Text] [Related]
66. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272 [TBL] [Abstract][Full Text] [Related]
67. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Sharom FJ; Lu P; Liu R; Yu X Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):621-30. PubMed ID: 9677321 [TBL] [Abstract][Full Text] [Related]
68. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077 [TBL] [Abstract][Full Text] [Related]
69. Drug-stimulated ATPase activity of the human P-glycoprotein. Scarborough GA J Bioenerg Biomembr; 1995 Feb; 27(1):37-41. PubMed ID: 7629050 [TBL] [Abstract][Full Text] [Related]
70. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. Weisburg JH; Roepe PD; Dzekunov S; Scheinberg DA J Biol Chem; 1999 Apr; 274(16):10877-88. PubMed ID: 10196165 [TBL] [Abstract][Full Text] [Related]
71. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440 [TBL] [Abstract][Full Text] [Related]
72. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Tainton KM; Smyth MJ; Jackson JT; Tanner JE; Cerruti L; Jane SM; Darcy PK; Johnstone RW Cell Death Differ; 2004 Sep; 11(9):1028-37. PubMed ID: 15131592 [TBL] [Abstract][Full Text] [Related]
73. Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. Reungpatthanaphong P; Dechsupa S; Meesungnoen J; Loetchutinat C; Mankhetkorn S J Biochem Biophys Methods; 2003 Jul; 57(1):1-16. PubMed ID: 12834959 [TBL] [Abstract][Full Text] [Related]
74. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821 [TBL] [Abstract][Full Text] [Related]
75. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. Borgnia MJ; Eytan GD; Assaraf YG J Biol Chem; 1996 Feb; 271(6):3163-71. PubMed ID: 8621716 [TBL] [Abstract][Full Text] [Related]
76. Modulation of P-glycoprotein by Stemona alkaloids in human multidrug resistance leukemic cells and structural relationships. Umsumarng S; Pitchakarn P; Yodkeeree S; Punfa W; Mapoung S; Ramli RA; Pyne SG; Limtrakul P Phytomedicine; 2017 Oct; 34():182-190. PubMed ID: 28899501 [TBL] [Abstract][Full Text] [Related]
77. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells. Chaisit T; Siripong P; Jianmongkol S Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559 [TBL] [Abstract][Full Text] [Related]
78. A tamoxifen derivative, N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine, selectively targets P-glycoprotein-positive multidrug resistant Chinese hamster cells. Georges E; Lian J; Laberge R Biochem Pharmacol; 2014 Jul; 90(2):107-14. PubMed ID: 24821111 [TBL] [Abstract][Full Text] [Related]
79. Establishment of a P-glycoprotein substrate screening model and its preliminary application. Wang Y; Cao J; Zeng S World J Gastroenterol; 2004 May; 10(9):1365-8. PubMed ID: 15112361 [TBL] [Abstract][Full Text] [Related]
80. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Ashmore SM; Thomas DG; Darling JL Anticancer Drugs; 1999 Nov; 10(10):861-72. PubMed ID: 10630353 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]